Skip to main content

Table 1 Baseline Characteristics according to the presence or absence of MSK symptoms in the last month in the studied CNO patients (n = 68)

From: Musculoskeletal symptoms and their impact on health-related quality of life in chronic nonbacterial osteomyelitis patients

Variable n (%), median (min-max), mean ± SD

Study sample (n = 68)

Musculoskeletal manifestations

p value

With (n = 45)

Without (n = 23)

Age, years

 < 20

 20–40

 > 40

14 (5–62)

59 (86.8)

6 (8.8)

3 (4.4)

15 (5–62)

36 (80)

6 (13.3)

3 (6.7)

13 (8–19)

23 (100)

0

0

0.151

0.083

Gender

    

 Male

 Female

23 (33.8)

45 (66.2)

10 (22.2)

35 (77.8)

13 (56.5)

10 (43.5)

0.005*

The survey completed by

    

 The patient

 The parent

13 (19.1)

55 (80.9)

11 (24.4)

34 (75.6)

2 (8.7)

21 (91.3)

0.192

Country

    

 USA

 UK

 Others

35 (51.5)

14 (20.6)

19 (27.9)

21 (46.7)

11 (24.4)

13 (28.9)

14 (60.9)

3 (13)

6 (26.1)

0.449

Disease duration, years

 < 5, n (%)

 ≥ 5, n (%)

4.75 (0.17-24)

34 (50)

34 (50)

5 (0.17-24)

21 (46.7)

24 (53.3)

4 (0.33-13)

13 (56.5)

10 (43.5)

0.155

0.609

Number of bones affected by CNO

 < 10, n (%)

 ≥ 10, n (%)

5 (1–24)

59 (86.8)

9 (13.2)

5 (1–24)

37 (82.2)

8 (17.8)

4 (1–18)

22 (95.7)

1 (4.3)

0.282

0.153

Associated comorbid conditions

 Psoriasis

 Juvenile idiopathic arthritis

 Inflammatory bowel disease

 Others

37 (54.4)

12 (17.6)

6 (8.8)

6 (8.8)

12 (17.6)

28 (62.2)

11 (24.4)

5 (11.1)

6 (13.3)

8 (17.8)

9 (39.1)

1 (4.3)

1 (4.3)

0

4 (17.4)

0.070

0.048*

0.565

0.089

1

Treatments used for CNO disease

    

Corticosteroids

Bisphosphonates

21 (30.9)

24 (35.3)

17 (37.8)

21 (46.7)

4 (17.4)

3 (13)

0.085

0.006*

cDMARDs

    

 Sulfasalazine

 Methotrexate

8 (11.8)

28 (41.2)

5 (11.1)

22 (48.9)

3 (13)

6 (26.1)

0.815

0.071

bDMARDs

    

 Adalimumab

 Etanercept

 Infliximab

 Golimumab

 Certolizumab pegol

 Abatacept

 Tocilizumab

9 (13.2)

7 (10.3)

11 (16.2)

3 (4.4)

1 (1.5)

1 (1.5)

2 (2.9)

6 (13.3)

6 (13.3)

10 (22.2)

3 (6.7)

1 (2.2)

1 (2.2)

2 (4.4)

3 (13)

1 (4.3)

1 (4.3)

0 (0)

0 (0)

0 (0)

0 (0)

0.973

0.249

0.058

0.205

0.471

0.471

0.305

Others

    

 NSAIDs

 Pain medications

 Antibiotics

 Physical therapy

 Surgery

 Radiation

52 (76.5)

21 (30.9)

5 (7.4)

28 (41.2)

9 (13.2)

1 (1.5)

34 (75.6)

19 (42.2)

5 (11.1)

20 (44.4)

7 (15.6)

1 (2.2)

18 (78.3)

2 (8.7)

0 (0)

8 (34.8)

2 (8.7)

0 (0)

0.804

0.005*

0.097

0.444

0.43

0.471

  1. *p < 0.05
Back to article page

Pediatric Rheumatology

ISSN: 1546-0096